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Different genetic aberrations of BRAF have been reported in various malignancies. BRAF
is member of the RAS/RAF/MEK/ERK pathway and constitutive activity of this pathway can
lead to increased cellular growth, invasion, and metastasis. The most common activating
BRAF mutation in colorectal cancer is the V600E mutation, which is present in 5–15% of
all tumors, and up to 80% of tumors with high microsatellite instability (MSI) harbor this
mutation. BRAF mutation is associated with proximal location, higher age, female gender,
MSI-H, high grade, and mucinous histology, and is a marker of poor prognosis in colorectal
cancer. The role of BRAF mutation as a predictive marker in respect of EGFR targeted
treatments is controversial. BRAF V600 selective inhibitors have been approved for the
treatment of V600 mutation positive metastatic melanoma, but the response rates in col-
orectal cancer are poor. This might be due to innate resistance mechanisms of colorectal
cancers against the treatment solely targeting BRAF. To overcome resistance the com-
bination of treatments, simultaneous inhibition of BRAF and MEK or PI3K/mTOR, might
emerge as a successful therapeutic concept.
Keywords: BRAF, colorectal cancer, Lynch syndrome, microsatellite instability, V600E, V600K, vemurafenib,
dabrafenib
INTRODUCTION
BRAF (v-raf murine sarcoma viral oncogene homolog B1) is a
serine/threonine protein kinase of the RAF family. RAF proteins
are kinases in RAS/RAF/MEK/ERK pathway. ARAF and CRAF are
other family members of the RAF family, however, BRAF displays
the best binding to RAS and has the highest phosphorylating
activity (1). The RAS/RAF/MEK/ERK pathway usually responds
to growth factors and cytokines. However, aberrant signaling of
this pathway, for example by constantly active kinases can result in
abnormal cellular growth, invasion, and metastasis (2).
BRAF is mutated at a high frequency in several cancers,
although also amplification of the protein and aberrant splicing
variants have been reported as well (1). The BRAF V600E muta-
tion, deriving from a point mutation of the DNA (1799T→A)
is the most common BRAF mutation and accounts for around
90% (3). BRAF V600E mutation is most prominent in melanoma
(40–60%), papillary thyroid carcinoma (45%), low grade serous
ovarian carcinoma (35%), and in colorectal adenocarcinoma (5–
15%) (4). Other BRAF mutations include V600K and V600D/R,
accounting for 16–29% and 3% of all BRAF mutations in
melanoma, respectively (5, 6). Another activating BRAF mutation
that is almost exclusively found in pilocytic astrocytomas is the
KIAA1549-BRAF fusion, found in 66–100% of these tumors (7, 8).
Colorectal cancer development and progression can be divided
into two separate pathways: chromosomal instability pathway and
microsatellite instability (MSI) pathway. In roughly 75% of the
cases, colorectal cancer develops through chromosomal instability
pathway, and these tumors can harbor APC mutations (>90%),
KRAS mutations (50%), TP53 mutations (70%), and allelic loss
of 18q (80%) (9). MSI pathway covers approximately 15% of
sporadic colorectal cancers and almost all Lynch syndrome (LS)
cases. In cancers developing through the MSI pathway the DNA
mismatch repair (MMR) function is dysfunctional, which leads
to insertions and/or deletions of nucleotide repeats in the DNA
(9). Remaining tumors belong to CpG island methylator path-
way (CIMP) and Serrated Adenoma Pathway, and approximately
one third of CIMP tumors are MSI-H while most of the serrated
tumors have a deficient MLH1 gene due to promoter methylation.
DETECTION OF BRAF MUTATION IN COLORECTAL CANCER
Until recently the detection of BRAF mutations was performed
with Sanger sequencing or PCR-based assays. These methods
require representative amount of malignant cells and extraction
of the DNA. For specimens with a low content of tumor tissue, the
DNA based protocols thus might not be sensitive enough to detect
the BRAF mutations. A recent report compared the detection of
BRAF mutations between two next generation sequencing (NGS)
technologies and Sanger sequencing/q-PCR and found NGS to
be reliable in detecting BRAF mutations and other standard-of-
care mutations (10). Immunohistochemical (IHC) detection of
BRAF V600E with a mutation specific antibody (clone VE1) was
first described in metastatic melanoma and papillary thyroid car-
cinoma (11), and the antibody is currently commercially available
(Figures 1A,B). The advantage of IHC lies in the minimal amount
of the needed tissue and the availability of this technique in most
pathological laboratories. Colorectal cancer has been analyzed
with the BRAF V600E mutation specific antibody and most studies
find high sensitivities and specificities (98.8–100%) in comparison
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FIGURE 1 | RAS-RAF pathway and immunohistochemical staining of
colorectal cancer specimens with BRAF V600E mutation specific
monoclonal antibody. (A) Strong immunopositivity in cancer cells with a
BRAF V600E mutation. (B) No staining of cancer cells in a specimen
without BRAF V600E mutation. Original magnifications are 200×. (C)
Schematic RAS-RAF pathway (orange boxes) and inhibitors of components
of this pathway (blue boxes). Arrows indicate an activation process, and
blocked arrows an inhibition process.
with PCR-based methods or sequencing (12–16). In one study
however, the sensitivity and specificity were only 71 and 74%,
respectively (17). The choice of the positive control tissue and the
amplification protocol seem to be crucial in successful detection
of BRAF V600E mutation by IHC (16).
OCCURRENCE OF BRAF MUTATION IN COLORECTAL CANCER
The frequency of BRAF V600E mutation differs in tumors with
high MSI (MSI-H) compared to tumors that are microsatellite-
stable (MSS). Whereas BRAF V600E mutation frequencies below
10% are reported for MSS tumors (3, 15, 16, 18), they range from
13 to 78% in MSI-H tumors, including cases with germ line muta-
tion for one of the MMR genes (12, 15, 16, 18). In our consecutive
colorectal cancer material BRAF V600E mutation was found in
78% of MSI-H and 8% of MSS tumors (p< 0.0001) (16). A recent
study reported BRAF V600E mutation in 100% of sessile serrated
adenomas/polyps, 94% of traditional serrated adenoma, and in
62% of micro vesicular hyperplastic polyps (19). BRAF V600E
mutation in microvesicular hyperplastic polyps might indicate
the polyps that have a higher risk for progression to adeno-
mas/adenocarcinomas (19). The BRAF V600K mutation seems to
be a rare event in colorectal cancer, at least in MSI-H tumors (16).
SIGNIFICANCE OF BRAF MUTATION IN COLORECTAL CANCER
CONNECTION TO CLINICOPATHOLOGICAL PARAMETERS
BRAF V600E mutations are associated with several clinicopatho-
logical parameters and the ones most often reported are: proximal
location, higher age, female gender, MSI-H, high grade, and muci-
nous histology (16, 20–26). Whereas in most studies colorectal
cancers are classified into proximal and distal location, Yamauchi
et al. described a gradual linear increase of BRAF mutation, MSI-
H, and high CpG island methylator phenotype frequency from
rectum to ascending colon (27). The frequencies of all three fac-
tors were lower in cecum than in ascending colon, indicating that
cecal cancers are a unique subtype (27).
High microsatellite instability is associated with a higher num-
ber of harvested lymph nodes (28, 29), and a recent study reported
that BRAF V600E mutation was associated with a lower node har-
vest in the MSI-H group in colon cancer (30). The lymph node
count is a predictor of long-term survival in colorectal cancer.
Rather than just reflecting the quality of care, the lymph node
count might be associated with several factors such as tumor
location, tumor and host genetics, and immune interaction (30).
PROGNOSTIC ROLE
BRAF V600E mutation is associated with reduced survival (overall
survival, disease-free survival, or cancer-specific survival) espe-
cially in MSS tumors (Table 1) (18, 21, 23, 24, 26, 31, 32). Its
role in MSI-H tumors is not so clearly defined; while some studies
attribute MSI-H tumors with excellent survival regardless of BRAF
status (18), BRAF V600E mutation decreased overall survival inde-
pendent of MSI status in another report (25). In addition, BRAF
V600E mutation was associated with poor prognosis in all groups
of advanced colorectal cancer (33) and was an independent prog-
nostic factor for overall survival and cancer-specific survival in a
pooled stage II/III cohort (22). In a couple of studies, no prognos-
tic role was found to be associated with BRAF mutation (Table 1)
(34, 35). Finally, in a meta-analysis that included 26 colorectal
cancer studies, BRAF mutation was found to increase the risk of
mortality (HR= 2.25, 95% CI: 1.82–2.83) (36).
PREDICTIVE ROLE
It has been suggested that in order for metastatic colorectal
cancer patients to receive a response for treatment with mono-
clonal antibodies targeting EGFR (panitumumab and cetuximab,
Figure 1C), the BRAF gene needs to be present as wild-type (37,
38). Yuan et al. recently concluded in a meta-analysis that BRAF
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Table 1 | BRAF mutation as prognostic factor in colorectal cancer.
BRAF mutation
as prognostic
factor
Tested for BRAF
mutation
(BRAF mutated)
Comments Reference
Independent 911 (87) Stage II-IV, microsatellite-stable tumors, age, stage, tumor site, and CpG island
methylator phenotype adjusted, reduced OS, HR=3.06, 95% CI: 2.06–4.54; (1.0
reference BRAF wt)
Samowitz et al. (18)
Independent 1307 (103) Stage II/III, reduced OS, HR=1.78, 95% CI: 1.15–2.76; (1.0 reference BRAF wt) Roth et al. (21)
Independent 297 (59) Stage II/III, reduced OS, HR=0.45, 95% CI: 0.25–0.8, and reduced cancer-specific
survival, HR=0.47, 95% CI: 0.22–0.99; (1.0 reference BRAF mut)
Farina-Sarasqueta
et al. (22)
Independent 506 (75) Stage III, reduced OS, HR=1.66; 95% CI: 1.05–2.63; (1.0 reference BRAF wt) Ogino et al. (23)
Independent 475 (56) Stage I-III, reduced OS, HR=1.79, 95% CI: 1.05–3.05; (1.0 reference BRAF wt) Kalady et al. (25)
Independent 196 (35) Stage I-IV, reduced cancer-specific survival, HR=2.00, 95% CI: 1.16–3.43; (1.0
reference BRAF wt)
Eklöf et al. (26)
Independent 1253 (182) Stage I-IV, higher cancer-specific mortality in microsatellite-stable tumors, HR=1.60,
95% CI: 1.12–2.28; (1.0 reference MSS/BRAF wt)
Lochhead et al. (32)
Non-independent 711 (56) Advanced CRC, reduced OS, HR=1.82; 95% CI: 1.36–2.43; (1.0 reference BRAF wt) Richman et al. (33)
Non-independent 181 (20) Stage I-IV, proficient DNA mismatch repair, stage-adjusted reduced OS and DSF,
HR=6.63, 95% CI: 2.60–16.94 and HR=6.08, 95% CI: 2.11–17.56; (1.0 reference
KRAS/BRAF wt)
Pai et al. (24)
Non-independent 243 (18) Metastatic CRC, reduced PSF, HR=2.39, 95% CI: 1.36–4.21; (1.0 reference
KRAS/BRAF wt)
Peeters et al. (31)
No prognostic
significance
490 (77) Stage II/III, no effect on DFS, HR=1.0, 95% CI: 0.6–1.6; no effect on OS, HR=1.2,
95% CI: 0.8–1.8; (1.0 reference BRAF wt)
French et al. (34)
No prognostic
significance
822 (10%) Stage II/III, no effect on DFS, HR=1.07, 95% CI: 0.66–1.73; (1.0 reference BRAF wt) Mouradov et al. (35)
CRC, colorectal cancer; DSF, disease-free survival; mut, mutant; OS, overall survival; PFS, progression-free survival; wt, wild-type.
mutation is a predictive biomarker and indicates poor prognosis
when metastatic colorectal cancer patients are treated with mon-
oclonal antibodies against EGFR (39). In contrast to these results,
a recent guideline does not recommend testing for BRAF muta-
tions in colorectal cancer patients before anti-EGFR treatment
(40). Garcia-Alfonso et al. (40) conclude that BRAF mutation is
not predictive for anti-EGFR treatment in randomized trials. For
patients (KRAS wild-type metastatic colorectal tumors) treated
with chemotherapy/bevacizumab with or without cetuximab in
the phase III CAIRO2 study, BRAF mutation was correlated to
a shorter progression-free survival and overall survival, in both
treatment arms (41). Similarly, BRAF mutation was not predictive
for treatment with cetuximab, but was a marker of poor progno-
sis in metastatic colorectal cancer patients (KRAS wild-type) that
were randomly assigned to treatment with FOLFIRI (irinotecan,
fluorouracil, leucovorin) with or without cetuximab in the CRYS-
TAL study (42). The pooled analysis of the CRYSTAL and OPUS
trials on metastatic colorectal cancer showed that BRAF muta-
tion was not predictive for treatment with cetuximab in KRAS
wild-type patients, but indicated poor prognosis (43). Finally, in a
retrospective analysis of the PRIME study, BRAF mutation was not
predictive for overall or progression-free survival in KRAS wild-
type patients treated with FOLFOX4 (oxaliplatin, fluorouracil,
leucovorin) with or without panitumumab (44).
As for treatment with standard chemotherapy agents (fluo-
rouracil with irinotecan or oxaliplatin), BRAF V600E mutation
was not predictive (33). Similarly, BRAF mutation was not pre-
dictive for fluorouracil-based therapy in mostly stage II colorec-
tal cancer (45). A non-significant trend for better survival with
fluorouracil/leucovorin+ irinotecan (vs. fluorouracil/leucovorin
alone) was detected in colorectal cancer stage III patients with
BRAF V600E mutation (23).
ROLE IN IDENTIFYING LS PATIENTS
Lynch syndrome is a hereditary form of colorectal cancer that
accounts for 1–3% of all CRC cases. It is the most common form
of hereditary CRC and is caused by a germ line mutation of one of
the MMR genes (46). As not all LS patients fulfill the Amsterdam II
criteria or revised Bethesda guidelines, not all of them are detected
in the routine clinical setting (47, 48). BRAF is usually present as
wild-type in LS patients, and only 1.4% of the LS patients carry
a BRAF V600E mutation (49). In sporadic colorectal cancer the
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BRAF V600E mutation rate ranges from 5 to 15% (4), and in the
MSI-H group of consecutive primary colorectal cancers the BRAF
V600E mutation rate reached 78% (16). This has led to the sugges-
tion that the detection of BRAF V600E mutation might be a useful
additional tool in finding LS patients, and several recent studies
have used BRAF V600E IHC to implement this step (12, 15, 16).
BRAF INHIBITORS IN TREATMENT OF CANCER
The first RAF inhibitor, sorafenib, was not effective in clinical use
for metastatic melanoma, as it did not improve median overall
survival in randomized, double-blind, placebo-controlled phase
III studies, when given in combination with paclitaxel and carbo-
platin as second-line treatment or to chemotherapy-naïve patients
(50–52). The reason for the disappointing results with sorafenib
in melanoma might be that this multi-targeted tyrosine kinase
inhibitor has a higher affinity for isoforms other than BRAF
and targets several other pathways as well (50, 53). However, in
advanced hepatocellular carcinoma, the median survival time was
increased by nearly 3 month in patients treated with sorafenib,
in a phase III, double-blind, placebo-controlled trial (54). Vemu-
rafenib (PLX4032) and dabrafenib (GSK2118436) are approved
for treatment of unresectable or metastatic melanoma (Food and
Drug Administration) and vemurafenib is also approved by the
European commission/European Medicines Agency. Both selec-
tively inhibit the BRAF V600 mutated form of BRAF, inhibit
phosphorylation of ERK, and have high clinical response rates
in melanoma patients (Figure 1C) (50, 53). Whereas patients with
BRAF V600 mutated melanomas had a clear survival benefit when
treated with BRAF inhibitors, the response rate in metastatic col-
orectal carcinoma (harboring BRAF V600E mutation) was poor,
since only one patient (1/19) displayed a partial response and 4
out of 19 patients a minor response (55, 56). It has been noted
already in xenografts from BRAF V600E mutant colorectal cancer
cell lines that tumor growth inhibition was most efficient when
vemurafenib was combined with EGRF or Akt inhibitors and/or
chemotherapeutic agents (57).
RESISTANCE TO BRAF INHIBITION IN MELANOMA AND
COLORECTAL CANCER
BRAF V600E mutant melanomas initially have a good response
rate. However, most of them acquire a drug resistance after 6–
7 months, and roughly 10% have tumor progression at earlier
stages (53, 55). BRAF V600E mutated colorectal cancer on the
contrary, seems to display an innate resistance to inhibition with
BRAF inhibitors, which was also demonstrated in colorectal cancer
cell lines (55, 58, 59). The mechanisms of resistance can be grouped
according to their dependence on ERK signaling (60). ERK-
dependent resistance mechanisms can occur via activating MEK1
mutations (61), activating NRAS mutations (62), COT overex-
pression (63), elevated CRAS activity (64), BRAF V600E alterna-
tive splicing or amplification (65). ERK-independent mechanisms
include the PI3K pathway (66), overexpression of PDGFRβ (62),
IGF1R activation (67), and hepatocyte growth factor (59). Impor-
tantly,Romano et al. report that different mechanisms of resistance
can occur in the same patient at different metastatic locations (68).
In BRAF V600E mutant colorectal cancer cells the amplifica-
tion of the BRAF gene was identified as mechanism of resistance
to MEK and BRAF inhibition (69). Two studies detected the
critical role of EGFR in BRAF V600E mutant colorectal cancer
cells that did not respond to BRAF inhibition (58, 70). Corocan
et al. reported that BRAF V600E mutant colorectal cancer cell
lines harbored more phospho-EGRF than melanomas with the
same mutation, and reactivated MAPK signaling via EGFR (58).
Prahallad et al. described a rapid feedback activation of EGFR (via
CDC25C inhibition) upon RAF inhibition, and EGFR was highly
expressed BRAF V600E mutant colorectal cancer cells as compared
to BRAF V600E mutant melanoma cells (70).
OVERCOMING OF RESISTANCE AND COMBINATION
TREATMENTS
To overcome resistances upon treatment with a BRAF inhibitor,
targeting novel downstream kinases of the pathway or combina-
tion of therapies might be helpful. As for melanoma treatment, the
combination of vemurafenib with the HDM2 inhibitor nutlin-3
(leading to p53 restoration), has shown synergistic effect on induc-
ing apoptosis and suppressing tumor growth in melanoma cell
lines and xenografts (71). Novel combinatorial treatment options
include BRAF inhibition simultaneously with PI3K/mTOR as
shown in colorectal cell lines and animal models (72–74). Coffee
et al. used the Apc-Braf mouse model (mice bearing a BrafV600E
allele) and showed that concomitant inhibition of PI3K/mTOR
and BRAF resulted in tumor regression due to induction of apop-
tosis and decrease in proliferation (73). Also Rad et al. reported
the potent growth inhibitory effect of combined BRAF/PI3K inhi-
bition on xenografts of BRAF mutant mouse and human col-
orectal cancer cell lines (74). Furthermore, MEK inhibition alone
caused regression of xenografted and orthotopically transplanted
tumors, and reduced proliferation in tumors of BrafLSL-V637E/+
mice (orthologous to human BRAF V600E mutation) (74). A
combined inhibition of BRAF (dabrafenib 150 mg) and MEK1/2
(trametinib, 1 or 2 mg) was performed in metastatic melanoma
patients with BRAF V600E mutation, in a open-label phase II
study with randomly assigned patients. Both median progression-
free survival (9.4 vs. 5.8 months) and complete/partial response
(76 vs. 54%) were significantly improved in the combination
group (150+ 2 mg) vs. dabrafenib immunotherapy (75). Both
dabrafenib and trametinib, were recently (May 2013) approved
by the Food and Drug Administration for treatment of metasta-
tic/inoperable melanoma (Figure 1C).
CONCLUSION
BRAF V600E mutation is a marker of poor prognosis in colorec-
tal cancer. Detection of this mutation can also be used to identify
LS patients. Targeted treatment of BRAF V600E mutation is in
use in advanced melanoma. However, the response is short-lived
in melanoma patients, due to the development of acquired resis-
tance. In colorectal cancer targeted treatment of mutated BRAF is
not feasible due to the innate resistance. New insights into possible
resistance mechanisms were reported recently, and combinator-
ial treatment options might impact therapy of tumors carrying a
BRAF mutation.
AUTHORS’ NOTE
After acceptance of this review, a novel study reported the com-
bined use of BRAF V600E and MMR immunohistochemistry as a
prognostic tool in colorectal cancer (Toon CW, Chou A, DeSilva
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K, Chan J, Patterson J, Clarkson A, et al. BRAFV600E immunohis-
tochemistry in conjunction with mismatch repair status predicts
survival in patients with colorectal cancer. Modern Pathol (2013)
Oct 25. doi:10.1038/modpathol.2013.200). The authors restricted
their analysis to only immunohistochemistry of BRAF V600E
and MMR status on 1426 consecutive colorectal cancer cases,
and found that MSS/BRAF V600E mutant tumor status was a
marker for poor prognosis in univariate analysis when compared
to MSS/BRAF wild type tumors (HR= 1.79, 95% CI: 1.24–2.60).
Immunohistochemical screening for BRAF V600E mutation and
MMR gene expression thus can facilitate the detection of Lynch
syndrome patients and can also identify subgroups with a poor
prognosis.
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